Literature DB >> 27694308

Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells.

Lisa Rank1, Sebastian Veith1,2, Eva C Gwosch3,4, Janine Demgenski1, Magdalena Ganz3,4, Marjolijn C Jongmans5,6, Christopher Vogel1, Arthur Fischbach1,4, Stefanie Buerger7, Jan M F Fischer1,4, Tabea Zubel1,4, Anna Stier1, Christina Renner1, Michael Schmalz8, Sascha Beneke1,9, Marcus Groettrup7,10, Roland P Kuiper5, Alexander Bürkle1, Elisa Ferrando-May3, Aswin Mangerich11.   

Abstract

Genotoxic stress activates PARP1, resulting in the post-translational modification of proteins with poly(ADP-ribose) (PAR). We genetically deleted PARP1 in one of the most widely used human cell systems, i.e. HeLa cells, via TALEN-mediated gene targeting. After comprehensive characterization of these cells during genotoxic stress, we analyzed structure-function relationships of PARP1 by reconstituting PARP1 KO cells with a series of PARP1 variants. Firstly, we verified that the PARP1\E988K mutant exhibits mono-ADP-ribosylation activity and we demonstrate that the PARP1\L713F mutant is constitutively active in cells. Secondly, both mutants exhibit distinct recruitment kinetics to sites of laser-induced DNA damage, which can potentially be attributed to non-covalent PARP1-PAR interaction via several PAR binding motifs. Thirdly, both mutants had distinct functional consequences in cellular patho-physiology, i.e. PARP1\L713F expression triggered apoptosis, whereas PARP1\E988K reconstitution caused a DNA-damage-induced G2 arrest. Importantly, both effects could be rescued by PARP inhibitor treatment, indicating distinct cellular consequences of constitutive PARylation and mono(ADP-ribosyl)ation. Finally, we demonstrate that the cancer-associated PARP1 SNP variant (V762A) as well as a newly identified inherited PARP1 mutation (F304L\V762A) present in a patient with pediatric colorectal carcinoma exhibit altered biochemical and cellular properties, thereby potentially supporting human carcinogenesis. Together, we establish a novel cellular model for PARylation research, by revealing strong structure-function relationships of natural and artificial PARP1 variants.
© The Author(s) 2016. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27694308      PMCID: PMC5137445          DOI: 10.1093/nar/gkw859

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  85 in total

1.  De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome.

Authors:  Alexander Hoischen; Bregje W M van Bon; Benjamín Rodríguez-Santiago; Christian Gilissen; Lisenka E L M Vissers; Petra de Vries; Irene Janssen; Bart van Lier; Rob Hastings; Sarah F Smithson; Ruth Newbury-Ecob; Susanne Kjaergaard; Judith Goodship; Ruth McGowan; Deborah Bartholdi; Anita Rauch; Maarit Peippo; Jan M Cobben; Dagmar Wieczorek; Gabriele Gillessen-Kaesbach; Joris A Veltman; Han G Brunner; Bert B B A de Vries
Journal:  Nat Genet       Date:  2011-06-26       Impact factor: 38.330

2.  Enzyme characteristics of recombinant poly(ADP-ribose) polymerases-1 of rat and human origin mirror the correlation between cellular poly(ADP-ribosyl)ation capacity and species-specific life span.

Authors:  Sascha Beneke; Anna-Lena Scherr; Viviane Ponath; Oliver Popp; Alexander Bürkle
Journal:  Mech Ageing Dev       Date:  2010-04-24       Impact factor: 5.432

3.  PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase.

Authors:  J C Amé; V Rolli; V Schreiber; C Niedergang; F Apiou; P Decker; S Muller; T Höger; J Ménissier-de Murcia; G de Murcia
Journal:  J Biol Chem       Date:  1999-06-18       Impact factor: 5.157

4.  Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos).

Authors:  Yingfei Wang; No Soo Kim; Jean-Francois Haince; Ho Chul Kang; Karen K David; Shaida A Andrabi; Guy G Poirier; Valina L Dawson; Ted M Dawson
Journal:  Sci Signal       Date:  2011-04-05       Impact factor: 8.192

5.  Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease.

Authors:  Z Q Wang; B Auer; L Stingl; H Berghammer; D Haidacher; M Schweiger; E F Wagner
Journal:  Genes Dev       Date:  1995-03-01       Impact factor: 11.361

Review 6.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

7.  PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites.

Authors:  Jean-François Haince; Darin McDonald; Amélie Rodrigue; Ugo Déry; Jean-Yves Masson; Michael J Hendzel; Guy G Poirier
Journal:  J Biol Chem       Date:  2007-11-19       Impact factor: 5.157

8.  PARP-1 Val762Ala polymorphism and risk of cancer: a meta-analysis based on 39 case-control studies.

Authors:  Qin Qin; Jing Lu; Hongcheng Zhu; Liping Xu; Hongyan Cheng; Liangliang Zhan; Xi Yang; Chi Zhang; Xinchen Sun
Journal:  PLoS One       Date:  2014-05-22       Impact factor: 3.240

9.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Authors:  Junko Murai; Shar-yin N Huang; Benu Brata Das; Amelie Renaud; Yiping Zhang; James H Doroshow; Jiuping Ji; Shunichi Takeda; Yves Pommier
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 13.312

10.  Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1.

Authors:  Sebastian Eustermann; Wing-Fung Wu; Marie-France Langelier; Ji-Chun Yang; Laura E Easton; Amanda A Riccio; John M Pascal; David Neuhaus
Journal:  Mol Cell       Date:  2015-11-25       Impact factor: 17.970

View more
  11 in total

1.  Comprehensive ADP-ribosylome analysis identifies tyrosine as an ADP-ribose acceptor site.

Authors:  Deena M Leslie Pedrioli; Mario Leutert; Vera Bilan; Kathrin Nowak; Kapila Gunasekera; Elena Ferrari; Ralph Imhof; Lars Malmström; Michael O Hottiger
Journal:  EMBO Rep       Date:  2018-06-28       Impact factor: 8.807

2.  PARP1 and XRCC1 exhibit a reciprocal relationship in genotoxic stress response.

Authors:  Julia M Reber; Jovana Božić-Petković; Michelle Lippmann; Marvin Mazzardo; Asisa Dilger; Rebecca Warmers; Alexander Bürkle; Aswin Mangerich
Journal:  Cell Biol Toxicol       Date:  2022-07-01       Impact factor: 6.691

3.  Kinetics of poly(ADP-ribosyl)ation, but not PARP1 itself, determines the cell fate in response to DNA damage in vitro and in vivo.

Authors:  Harald Schuhwerk; Christopher Bruhn; Kanstantsin Siniuk; Wookee Min; Suheda Erener; Paulius Grigaravicius; Annika Krüger; Elena Ferrari; Tabea Zubel; David Lazaro; Shamci Monajembashi; Kirstin Kiesow; Torsten Kroll; Alexander Bürkle; Aswin Mangerich; Michael Hottiger; Zhao-Qi Wang
Journal:  Nucleic Acids Res       Date:  2017-11-02       Impact factor: 16.971

4.  PARP1 depletion induces RIG-I-dependent signaling in human cancer cells.

Authors:  Rajib Ghosh; Sanchita Roy; Sonia Franco
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

5.  Real-time monitoring of PARP1-dependent PARylation by ATR-FTIR spectroscopy.

Authors:  Annika Krüger; Alexander Bürkle; Karin Hauser; Aswin Mangerich
Journal:  Nat Commun       Date:  2020-05-01       Impact factor: 14.919

6.  Poly(ADP-ribose) polymerase 1 accelerates vascular calcification by upregulating Runx2.

Authors:  Cheng Wang; Wenjing Xu; Jie An; Minglu Liang; Yiqing Li; Fengxiao Zhang; Qiangsong Tong; Kai Huang
Journal:  Nat Commun       Date:  2019-03-13       Impact factor: 14.919

7.  PARP1 regulates DNA damage-induced nucleolar-nucleoplasmic shuttling of WRN and XRCC1 in a toxicant and protein-specific manner.

Authors:  Sebastian Veith; Andrea Schink; Marina Engbrecht; Matthias Mack; Lisa Rank; Pascal Rossatti; Mariam Hakobyan; Denise Goly; Tanja Hefele; Marco Frensch; Arthur Fischbach; Alexander Bürkle; Aswin Mangerich
Journal:  Sci Rep       Date:  2019-07-11       Impact factor: 4.379

8.  MORC2 regulates DNA damage response through a PARP1-dependent pathway.

Authors:  Lin Zhang; Da-Qiang Li
Journal:  Nucleic Acids Res       Date:  2019-09-19       Impact factor: 16.971

Review 9.  The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers.

Authors:  Tatiana Kamaletdinova; Zahra Fanaei-Kahrani; Zhao-Qi Wang
Journal:  Cells       Date:  2019-12-12       Impact factor: 6.600

10.  Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo.

Authors:  Zhengping Shao; Brian J Lee; Élise Rouleau-Turcotte; Marie-France Langelier; Xiaohui Lin; Verna M Estes; John M Pascal; Shan Zha
Journal:  Nucleic Acids Res       Date:  2020-09-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.